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Abstract
Background: Tumor microenvironment inflammatory infiltration is proposed as a pro-
tumorigenic mechanism for prostate cancer with proinflammatory cytokines stimulating
androgen receptor (AR) activity. However, association with patient prognosis remains
unclear. This study derives an inflammatory gene signature associated with AR expression
and investigates CD3+ and CD8+ T‐lymphocyte infiltration association with AR and
prognosis.
Methods: Gene profiling of inflammatory related genes was performed on 71
prostate biopsies. Immunohistochemistry on 243 hormone‐naïve prostate cancers
was performed for CD3, CD8, AR, and phosphorylated AR tumor expression.
Results: Multiple proinflammatory genes were differentially expressed in association
with high AR expression compared with low AR expression including PI3KCA and MAKP8
(adjusted P< .05). High CD3+ and high CD8+ infiltration associated with reduced cancer‐
specific survival (P= .018 and P= .020, respectively). High CD3+ infiltration correlated
with high tumor cytoplasmic AR expression and if assessed together, they associated with
reduced cancer‐specific and 5‐year survival from 90% to 56% (P= .000179). High CD8+
cytotoxic infiltration associated with high androgen‐independent tumor nuclear AR serine
213 phosphorylation (correlation coefficient = 0.227; P= .003) and when assessed to-
gether associated with poor clinico‐pathological features including perineural invasion
(P= .001). Multiple genes involved in proinflammatory signaling pathways are upregulated
in high AR expressing prostate samples.
Conclusion: T‐lymphocyte infiltration in hormone‐naïve disease associates with
androgen‐independent driven disease and provides possible therapeutic targets to
reduce transformation from hormone‐naïve to castrate‐resistant disease.
K E YWORD S
androgen receptor, inflammation, phosphorylation, prostate cancer, T‐lymphocytes
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. The Prostate published by Wiley Periodicals LLC
1 | INTRODUCTION
Androgens activating the androgen receptor (AR) play a crucial role in
the development of 80% to 90% of prostate cancers (CaP). AR activa-
tion via induction of AR phosphorylation at serine 81 (pARser81)1‐4
promotes cell proliferation and reduces cell death, therefore current
therapies aim to inhibit AR activation directly or via depletion of an-
drogens by androgen deprivation therapy (ADT). However, despite
10‐year survival rates tripling over the past 40 years in the UK, over
300,000 men worldwide still die each year from CaP due to late stage
diagnosis and development of castrate‐resistant disease. This highlights
the need to understand the pathogenesis and progression of CaP fur-
ther.5 In addition to classical AR activation, the AR can be activated
independent of androgens through numerous pathways including
phosphatidylinositol‐3‐kinase (PI3K)/AKT, onterleukin‐6 (IL‐6)/Janus
kinase (JAK)/signal transducer and activator of transcription (STAT),
and Ras/Raf/mitogen‐activated protein kinase (MAPK) which result in
AR phosphorylation to promote transcriptional activity, protein stability
and the development of castrate‐resistant disease.4 For example,
phosphorylation of the AR at Serine 213 via PI3K/AKT signaling results
in activation of the AR via an androgen independent mechanism, the
PI3K/AKT pathway through loss of phosphatase and tensin homolog
(PTEN) is upregulated in 40% to 70% of CaPs.6,7
The prostate is an immune‐competent organ composed of in-
filtrating immune cells including macrophages, dendritic cells,
B‐lymphocytes, and T‐lymphocytes. Inflammatory changes observed
in CaP include increased inflammatory cell infiltration and proin-
flammatory cytokine expression, which promote multiple signaling
pathways linked with CaP development, such as PI3K/AKT and IL‐6/
JAK/STAT.8 It is hypothesized that these proliferative conditions
promote the dedifferentiation of prostate epithelial cells, activation
of AR signaling, and ultimately CaP development.
In CaP, the adaptive immune response is highly active and pro-
minent including cytotoxic T‐lymphocytes, helper T‐lymphocytes, and
regulatory T‐lymphocytes. CD4+ helper T‐lymphocytes induce (TNF)‐
related apoptosis, with a reduction in CD4+ infiltration in CaP, when
compared with benign prostatic hyperplasia and prostatic in-
traepithelial neoplasia, associating with poor clinico‐pathological
features including high Gleason sum and elevated prostate specific
antigen (PSA) concentration.9 Additionally, regulatory T‐cells (Tregs)
suppress and regulate T‐lymphocytes, with elevated Tregs within
the tumor microenvironment reducing the antitumor effects of
T‐lymphocytes. However, in CaP elevated Treg infiltration associates
with reduced cancer specific survival (CSS) in CaP.10,11 One cell type
regulated by Tregs are CD8+ cytotoxic cells which destroy microbes
and cancer cells via cytokine release, Fas signaling, or the perforin
pathway. In colorectal cancer, high CD8+ infiltration is associated
with favorable clinical outcomes and can be modulated to increase its
cytotoxic functions via immune checkpoint inhibitors which target
programmed cell death protein 1 or anti‐cytotoxic‐T‐lymphocyte‐
associated protein 4 (CTLA4). However, in CaP these immune
checkpoint inhibitors have shown little effect with high immune
checkpoint blockage resistance, with over expression of AR
significantly reducing CD8+ infiltration, PC‐1 and CTLA‐4 expression,
an correlating with tumor progression, increased serum PSA con-
centration, and the presence of metastases.12 Interestingly, loss of
PTEN, a common feature in CaP, is associated with increased CD8+
infiltration and reduced time to biochemical relapse, highlighting in-
teresting links between inflammation and AR. However, contra-
dictory reports have been published for each inflammatory cell type
depending on disease stage, tissue location, AR expression and cy-
tokine expression. Ultimately, further research is required to identify
important players of inflammatory driven CaP and potential ther-
apeutic targets or synergistic drug combinations. Therefore, we
aimed to derive an inflammatory gene expression signature asso-
ciated with high AR expression within a prostate biopsy and establish
if this signature is associated with more aggressive disease. Fur-
thermore, we aimed to determine the relationship between local
adaptive immune cell infiltration in hormone naive CaP and AR/
phosphorylated AR expression.
2 | METHODS
2.1 | Patient biopsy cohort
Prostate biopsies from 71 patients were collected between 2007 and
2012 via trans‐rectal ultrasound (TRUS) guided biopsies and snap
frozen upon extraction. Ethical approval was gained from the Mul-
ticentre Research Ethics Committee for Scotland (MREC/01/0/36)
and Local Research and Ethics Committees. An anonymized database
was available containing clinical information with all patient identi-
fiers removed and included age at biopsy, diagnosis, Gleason sum,
serum PSA concentration, and presence of metastases.
2.2 | Gene expression analysis
RNA was extracted from frozen TRUS biopsies using the RNease
Mini kit (Qiagen, UK). Biopsies were minced in RNA lysis buffer lysis
buffer and centrifuged in QiaShredder columns (Qiagen, UK) for
2minutes. Samples were transferred to a RNeasy mini column with
70% ethanol and centrifuged for 30 seconds. Samples were washed in
RW1 buffer followed by RNA wash buffer with ethanol buffer via
centrifugation for 30 seconds and eluted in RNase free water. Each
sample RNA was reverse‐transcribed by adding 1 µL oligo (dT) and
1 µL dNTPmix for 5minutes at 65°C. Each sample was then added to
4 µL 5X first strand buffer, 0.5 µL water, 0.5 µL SuperScript III reverse
transcriptase, 1 µL 0.1M DTT, and 1 µL RNaseOUT and incubated for
30minutes at 50°C followed by 15minutes at 70°C (Invitrogen, UK).
Ninety‐six primer pairs (Table S1) were pooled together and 0.5 µL
primer mix was added to each sample along with 2.5 µL TaqMan
PreAmp Master Mix (Thermo Fisher Scientific, UK), and 0.75 µL
water. These primers were pre‐selected based on their applicability
across a range of cancers, prostatic diseases, and inflammatory pro-
cesses. Samples were vortexed, centrifuged, and placed in a
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thermocycler for 10minutes at 95°C, 10 to 14 cycles for 15 seconds
at 95°C, and 4minutes at 60°C. Samples underwent exonuclease
treatment by adding 0.2 µL exonuclease I reaction buffer, 0.4 µL
exonuclease I, and 1.4 µL water and incubating for 30minutes at
37°C and 15minutes at 80°C (New England Biolabs, UK). Each
sample was diluted in five‐fold in TE buffer, added to 3 µL 2X SsoFast
EvaGreen Supermix (Bio‐Rad, UK) and 0.3 µL 20X DNA Binding Dye
sample loading reagent (Fluidigm, UK), and vortexed and centrifuged.
Individual primer pairs were added to 2.5 µL 2X assay loading re-
agent and 2.25 µL 1X DNA suspension buffer. Each individual primer
pair and sample was loaded into a 96.96 Dynamic Array IFC (Flui-
digm) and run on the Fluidigm Biomark HD system (Table S2).
2.3 | Immunohistochemistry
In total, 243 patients diagnosed with CaP were recruited from the
Greater Glasgow and Clyde Health Board between 2008 and 2009
(Biobank ethical approval for use of tissue, GG&C health board ethics
number 10/50704/60, Safe Haven ethical approval for use of clinical
information, GG&C health board ethics number 12/WS/0142).
An anonymized database was available containing clinical informa-
tion with all patient identifiers removed and included Gleason sum,
serum PSA concentration, presence of metastases, perineural
invasion, serum albumin concentration, C‐reactive protein
concentration, hormonal therapy, time to biochemical relapse, and
time to cancer specific death. All samples were gathered via
trans‐ultrasound guided biopsies.
Immunohistochemistry was performed for AR, pARser81, AR 213
phosphorylation (pARser213), Ki67 proliferation index, CD3, and CD8.
Sections were dewaxed in histoclear, rehydrated through graded
alcohol, and heated under pressure for 5minutes in Tris‐
ethylenediaminetetraacetic acid (Tris‐EDTA) (5 nM Trizma Base, 1mM
EDTA, pH8 or 9) for antigen retrieval. Sections were placed in 3% H2O2
for 30minutes and blocked for 30minutes in 1.5% or 5% horse serum in
Tris‐buffered saline. Antibodies for AR (M3562; Dako, UK), pARser81
(07‐1375; Millipore, UK), Ki67 (Clone MIB‐1; Dako), CD3 (RM‐9107‐S;
Thermo Fisher Scientific, UK), and CD8 (Clone C8/114b; Dako) were
incubated overnight at 4°C diluted at 1:100, 1:1000, 1:1000, 1:1000,
and 1:200 respectively. Antibody for pARser213 (IMG‐561; Imgenex, UK)
was incubated for 1 hour at room temperature diluted at 1:100. EnVi-
sion (Dako) or ImmPRESS detection kit (Vector Laboratories, UK) was
used to detect bound antibodies followed by 3,3‐diaminobenzidine
tetrahydrochloride (DAB, Dako). Samples were counterstained and de-
hydrated before being mounted with Di‐N‐butylephthalate in xylene
(DPX). Slides were scanned and visualized using Hamamatsu Nano-
Zoomer (Welwyn Garden City, UK) and Slidepath Digital Image Hub,
version 4.0.1 (Leica Biosystems, UK). Staining intensity for AR, pARser81,
and pARser213 was performed using a weighted histo‐score method for
both nuclear and cytoplasmic expression. In brief, the score was cal-
culated by sum of (1X % cells staining weakly positive) + (2X % cells
staining moderately positive) + (3X % cells staining strongly positive)
with a maximum of 300 (100% strongly stained) and a minimum of 0
(100% with no staining). Ki67, CD3, and CD8 expression was performed
by counting positive cells within three representative 0.6 × 0.6mm in-
tratumoural areas. Tissue staining intensity and positive cell counts
were scored by two independent observers.
2.4 | Statistical analysis
Statistical analysis was performed using SPSS version 22 for Windows.
Interclass correlation coefficients confirmed the weighted histoscores
and positive cell counts were consistent between two independent
observers. Receiver operator characteristic (ROC) curve analysis was
employed to determine high and low thresholds. CSS from diagnosis
was analyzed using Kaplan Meier log‐rank analysis from date of diag-
nosis to date of death from CaP. Cox‐regression, χ2 analysis, Pearson's
rank correlation, and Mann‐Whitney U tests were performed. Gene
expression analysis performed using R. Delta cycle thresholds values for
each biopsied sample were quantile normalized using the R package
limma.13 Hierarchical clustering (Ward.D2) of the normalized expression
data was then performed identifying two broad clusters. Genes differ-
entially expressed (DE) between clusters were then identified using the
R package limma.13 Heatmaps visualizing DE genes were generated
using the R/Bioconductor package ComplexHeatmap.14 Gene set en-
richment analysis was performed using the R/Bioconductor packages
clusterProfiler15 and ReactomePA.16 Regression analysis was per-
formed using the lm function form R package stats and the results
plotted using R package ggplot2. Boxplots were generated using the R
package ggpubr with significant difference between distributions cal-
culated using the Kruskal‐Wallis test.
3 | RESULTS
3.1 | Inflammatory gene expression in prostate
cancer
Inflammatory gene expression profiling was performed on 71
frozen TRUS prostate biopsies taken to diagnose a patient's pro-
static disease to determine an inflammatory gene signature and
whether this associates with high AR expression (Table S3). Un-
supervised hierarchal clustering separated the 71 prostate biop-
sies into two distinct classes (Figure 1A). Class 1 contained 11
patients of which 45.5% were CaP, 45.5% were benign, and 9%
were prostate intraepithelial neoplasia (PIN). Patients in class 1
were diagnosed with CaP at a median age of 69 years (inter-
quartile range [IQR]: 67‐71 years) with a median Gleason sum of 7
(IQR: 6‐7) and a median PSA concentration of 8.9 ng/mL (IQR: 5.8‐
17.1 ng/mL) at time of biopsy. Class 2 contained 60 patients of
which 23.3% were CaP, 31.7% were benign, and 5% were PIN.
Patients in class 2 were diagnosed with CaP at a median age of
69.5 years (IQR: 62.3‐74 years) with a median Gleason sum of 7
(IQR: 7‐7) and a median PSA concentration of 12.7 ng/mL (IQR:
9.1‐27.8 ng/mL) at time of biopsy.
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AR gene expression was trending towards being expressed
higher in class 1 biopsies compared with class 2 biopsies, however
this was not significant (Kruskal‐Wallis P = .051). Interestingly, the
gene for AR regulated PSA, KLK3, was significantly highly expressed
in class 1 samples versus class 2 (Kruskal‐Wallis P = 2.2 × 10−5). In
total, 54 out of 96 genes were computed as DE in class 1 versus class
2 biopsies, with the majority of upregulated genes being proin-
flammatory and protumorigenic including KLK3, EGFR, CASP1, TGFB1,
PI3CA, MAPK14, and NF‐ƙB (adjusted P value [padj] < .05) (Figure 1).
Furthermore, gene set enrichment analysis highlighted multiple
pathways significantly enriched in class 1 versus class 2 samples.
Among the enriched pathways, those relating to signaling by IL (20
genes) and IL‐4 and IL‐13 signaling (11 genes) were the most
significant (padj < 1 × 10−12) (Figure 2).
Subsequently, when the 19 CaP samples were selected for, these
samples fell into the same two classes as identified following gene
clustering analysis (Table S4). 26 out of the 96 genes were sig-
nificantly DE in cancer class 1 versus cancer class 2 of which 25 were
upregulated (Figure 1B). All genes DE in the cancer class 1 overlap
with the genes identified in all class 1 samples (Table S5). Despite AR
gene expression not being statistically different between cancer class
1 compared with cancer class 2 (Kruskal‐Wallis P = .15) (Figure S1A),
KLK3 was significantly higher in cancer class 1 versus cancer class 2
(Kruskal‐Wallis P = .0016) (Figure S1B). Interestingly, 6 out of the 26
gene expression profiles identified in both all class 1 samples and
cancer class 1 samples significantly correlated with higher AR ex-
pression including PI3CA, ERB3, IL1R, MAPK1, MAPK8, and PSMA
(P < .05) (Figure S1C‐H).
F IGURE 1 Differential gene expression analysis between patients from the frozen trans‐rectal ultrasound (TRUS) biopsy cohort by Fluidigm
array analysis. A, Heatmap demonstrating differentially expressed (DE) genes between all class 1 and all class 2 patients (P < .05). B, Table of top
15 DE expressed genes between cancer class 1 and cancer class 2 patients ordered by adjusted P value. Adjusted P value (Padj) < .05 used for
significant DE genes
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3.2 | Clinico‐pathological characteristics
Analysis was performed on 243 hormone‐naïve CaP patients, with
clinico‐pathological features and associations with CSS and the de-
velopment of biochemical relapse seen in Table 1. Patient char-
acteristics included age, Gleason sum, serum PSA concentration,
presence of metastases, perineural invasion, serum albumin con-
centration, C‐reactive protein concentration, time to biochemical
relapse, hormonal therapy receive, and time to cancer specific death.
At diagnosis, high Gleason sum (>7) (P < .0001), high serum PSA
concentration (>20 ng/mL) (P = .000419), presence of metastasis
(P < .0001), perineural invasion (P = .006), and high albumin con-
centration (P = .001) was associated with decreased CSS. Thirty‐eight
patients developed biochemical relapse with a mean time to bio-
chemical relapse of 2.20 years (IQR: 1.08‐2.90 years). The develop-
ment of biochemical relapse significantly associated with reduced
CSS (P = .000067). Eighty‐one patients died from CaP with a mean
time to death of 4.90 years (IQR: 4.50‐5.73 years).
F IGURE 2 Gene set enrichment analysis between class 1 and class 2 samples from the frozen TRUS biopsy cohort by Fluidigm array analysis.
Dot plot demonstrates the enriched pathways in class 1 samples compared with class 2 samples with color chart representing significance of
enriched pathways and circumference of dot representing the gene ratio. MAP, mitogen‐activated protein; NF‐κB, nuclear factor κB; TRUS,
trans‐rectal ultrasound
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3.3 | Androgen receptor and AR phosphorylation
expression analysis
As AR expression at the messenger RNA level associated
with expressions of inflammatory genes, we investigated if
AR expression and phosphorylation status associated with
inflammatory cell infiltrate in the tumor and microenvironment.
Tumor cytoplasmic (TC) AR expression ranged from 0 to 233
weighted histoscore units (WHU) with a median of 76 WHU (IQR:
40‐100). ROC curve analysis determined a threshold of 83 WHU
that separated TC AR expression into high and low. TC AR
expression significantly associated with reduced CSS (P = .001;
hazard ratio [HR] = 7.135 [95% confidence interval {CI}: 2.304‐
22.091]) and stratified 5‐year survival from 68% (low expression)
to 50% (high expression) but was not associated with time to
biochemical relapse (P = .758; HR = 0.941 [95% CI, 0.419‐2.110]).
TC AR expression associated with Gleason sum, serum PSA
concentrations, metastases, and perineural invasion at diagnosis
following χ2 analysis (Figure 3A,B).
TC pARser81 expression ranged from 0 to 197 WHU with a
median of 100 WHU (IQR: 100‐120). ROC curve analysis determined
a threshold of 110 WHU that separated TC pARser81 expression into
high and low. pARser81 expression significantly associated with re-
duced CSS (P = .046; HR = 1.950 (95% CI, 1.066‐3.567)) and stratified
5‐year survival from 65% (low expression) to 46% (high expression)
but was not associated with time to biochemical relapse (P = .911;
HR = 1.439 [95% CI, 0.492‐4.206]). Expression of TC pARser81
expression did not associate with any clinico‐pathological features
following chi‐squared analysis (Figure 3C,D).
TC pARser213 expression ranged from 0 to 203 WHU with a
median of 100 WHU (IQR: 93‐122). ROC curve analysis de-
termined a threshold of 99 WHU that separated TC pARser213
expression into high and low. TC pARser213 expression was not
associated with reduced CSS (P = .093; HR = 2.100 [95% CI, 0.441‐
1.921]) or time to biochemical relapse (P = .513; HR = 0.472 [95%
CI, 0.153‐1.456]). Expression of TC pARser213 expression did not
associate with any clinico‐pathological features following χ2 ana-
lysis (Figure 3E,F).
3.4 | Inflammatory cell infiltration expression
CD3+ T‐lymphocyte infiltration count ranged from 0 to 274 positive
cells with a median of 68 (IQR: 44‐105). ROC curve analysis determined
a threshold of 60 positive cells that separate CD3+ infiltration into high
and low (Figure 4A). CD3+ infiltration was associated with reduced CSS
(P = .018; HR =1.383 [95% CI, 0.591‐3.236]) and stratified 5‐year sur-
vival from 69% (low infiltration) to 54% (high infiltration) (Figure 5A).
CD3+ T‐lymphocyte infiltration was associated with Gleason sum and
perineural invasion at diagnosis following χ2 analysis and positively
correlated with elevated TC AR expression (Pearson's correlation
coefficient (c.c) = 0.278, P = .000232) (Table 2 and Figure S2D). High
CD3+ infiltration, when combined with high TC AR expression asso-
ciated with reduced CSS when compared with low expression
TABLE 1 Clinico‐pathological cohort characteristics and relationship with clinical outcome measures in 243 patients diagnosed with prostate
cancer and recruited from the Greater Glasgow and Clyde Health Board between 2008 and 2009; the number of patients in each group are
described along with the significance to cancer specific survival (CSS) and time to biochemical relapse (R); Kaplan Meier survival curves with log‐
rank tests were considered significant if P < .05
Clinico‐pathological characteristics Patient numbers n (%), total n = 243 Clinical outcome significance
Gleason sum 76 (31.3%), 85 (35.0%), 60 (24.7%), 22 (9.1%) CSS: P < .00001
(<7/7/>7/missing) R: P = .871
Serum PSA concentration 76 (31.3%), 53 (21.8%), 101 (41.6%), 13 (5.3%) CSS: P = .000419
(ng/mL) (<10/10‐20/>20/missing) R: P = .649
Metastases 132 (54.3%), 62 (25.5%), 49 (20.2%) CSS: P < .00001
(No/yes/missing) R: P = .209
Biochemical relapse 135 (55.6%), 38 (15.6%), 70 (28.8%) CSS: P = .000067
(No/yes/missing)
Hormonal therapy 67 (27.6%), 134 (55.1%), 42 (17.3%) CSS: P = .047
(No/yes/missing)
Perineural invasion 115 (47.3%), 99 (40.7%), 29 (11.9%) CSS: P = .006
(No/yes/missing) R: P = .094
Albumin, g/L 19 (7.8%), 170 (70%), 54 (22.2%) CSS: P = .001
(<35, >35, missing) R: P = .720
C‐reactive protein, mg/L 61 (25.1%), 41 (16.9%), 141 (58.0%) CSS: P = .113
(<10, >10, missing) R: P = .461
Abbreviation: PSA, prostate specific antigen.
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(P = .000179; HR= 2.118 [95% CI, 1.427‐3.144]) and reduced 5‐year
survival from 90% (low expression) to 56% (high expression), and as-
sociated with poor clinic‐pathological features including Gleason sum,
PSA concentration, metastases, perineural invasion, development of
biochemical relapse, and highly proliferative Ki67+ tumors (P = .000026,
P = .025, P = .001, P = .000043, P = .022, and P = .000349, respectively)
(Figure 5B).
Furthermore, cytotoxic CD8+ T‐lymphocyte infiltration count
ranged from 3 to 36 positive cells with a median of 15 (IQR :11‐19).
ROC curve analysis determined a threshold of 13 positive‐cells that
separated CD8+ infiltration into high and low (Figure 4B). CD8+
infiltration was associated with reduced CSS (P = .020; HR = 2.121
[95% CI, 0.773‐5.817]) and stratified 5‐year survival from 66%
(low infiltration) to 53% (high infiltration) (Figure 5C). CD8+
T‐lymphocyte infiltration was associated with Gleason sum, serum
PSA concentration, and perineural invasion at diagnosis and posi-
tively correlated with TC AR expression (c.c = 0.247, P = .001)
(Table 2 and Figure S2A). High CD8+ infiltration, when combined
with high TC AR expression associated with reduced CSS when
compared with low expression (P = .000257; HR = 1.945 [95% CI,
1.356‐2.790]) and 5‐year survival was reduced from 81% (low ex-
pression) to 57% (high expression). Additionally, high CD8+ in-
filtration combined with high TC AR expression was associated
with Gleason sum, PSA concentration, metastases, perineural in-
vasion, development of biochemical relapse, and highly pro-
liferative Ki67+ tumors (P = .000208, P = .000226, P = .016,
P = .000017, P = .002, and P = .000263, respectively) (Figure 5D).
Interestingly, cytotoxic CD8+ T‐lymphocyte infiltration did not
F IGURE 3 Androgen receptor (AR) and AR phosphorylation in 243 hormone‐naïve prostate cancer patients diagnosed with prostate cancer
and recruited from the Greater Glasgow and Clyde Health Board between 2008 and 2009. A, Low and high tumor cytoplasmic AR expression. B,
High tumor cytoplasmic AR expression associated with reduced cancer specific survival. C, Low and high tumor cytoplasmic pARser81 expression.
D, High tumor cytoplasmic pARser81 expression associated with reduced cancer specific survival. E, Low and high tumor cytoplasmic pARser213
expression. F, pARser213 expression was not associated with cancer specific survival within this cohort. Scale bars represent 100 µm and censor
lines indicate loss of patient follow‐up. pARser81, androgen receptor serine 81 phosphorylation; pARser213, androgen receptor serine 213
phosphorylatio
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correlate with androgen driven pARser81 within the cytoplasm or
nucleus of tumor cells (c.c = 0.152, P = .054 and c.c = 0.024, P = .762,
respectively) (Table 2). However, CD8+ T‐lymphocyte infiltration
significantly correlated with androgen‐independent AKT driven
pARser213 within the cytoplasm and nucleus (c.c = 0.185, P = .015
and c.c = 0.227, P = .003, respectively) (Table 2 and Figure S2B,C).
High CD8+ T‐lymphocyte infiltration combined with high tumor
nuclear pARser213 expression is significantly associated with poor
clinico‐pathological features including perineural invasion following
chi‐squared analysis (P = .001).
4 | DISCUSSION
Elevated inflammatory cells within the peripheral zone of the
prostate are linked with the development of CaP (relative risk = 1.3,
95% confidence interval = 1.10‐1.54).8,17 With this in mind, we
investigated how T‐lymphocyte infiltration associated with cancer
specific survival and the AR and the prognostic use of this for pa-
tients with Ca. Additionally, we aimed to investigate if a single TRUS
biopsy could be used to identify aggressive characteristics in CaP.
We found multiple proinflammatory genes DE in prostate biopsies
including NFƙB which has previously been reported to be upregu-
lated in CaP and seen to promote increased cellular proliferation,
ADT resistance, and induce antiapoptotic signals.18‐21 Furthermore,
we observed significant T‐lymphocyte infiltration in hormone‐naïve
CaP and a reduction in cancer specific survival which associated
with high AR expression and androgen‐independent AR serine
213 phosphorylation.
In contrast to our findings, many claim that inflammatory cell
infiltration delivers a protective environment and reduces the risk of
CaP.22,23 This is further reflected in various other cancers including
colorectal cancer and renal cell carcinoma whereby studies into
modulating the immune response to provoke an antitumour effects
F IGURE 4 Low and high T‐lymphocyte infiltration into the tumor microenvironment of 243 hormone naïve prostate cancer specimens
diagnosed with prostate cancer and recruited from the Greater Glasgow and Clyde Health Board between 2008 and 2009. A, Low and high
CD3+ T‐lymphocyte infiltration. B, Low and high CD8+ T‐lymphocyte infiltration. Scale bars represent 100 µm
1360 | McALLISTER ET AL.
have proved successful.24,25 However, contradictory studies, in con-
junction with our own, have identified a protumorigenic response
associated with local inflammatory infiltration within the tumor mi-
croenvironment. Chronic inflammation within the prostate is linked
with the dedifferentiation of the prostatic epithelium and pro‐
tumourigenesis with multiple pathways dysregulated that alter the
tumor microenvironment and provide a highly proliferative en-
vironment for CaP.26,27 Interestingly, in CaP it is hypothesized that it
F IGURE 5 T‐lymphocyte infiltration in prostate cancer and association with androgen receptor expression in 243 patients diagnosed with
prostate cancer and recruited from the Greater Glasgow and Clyde Health Board between 2008 and 2009. A, CD3+ T‐lymphocyte infiltration
reduced survival from 6.71 to 5.83 years. B, High CD3+ infiltration and high tumor cytoplasmic androgen receptor expression reduced survival
from 6.94 to 5.12 years. C, CD8+ T‐lymphocyte infiltration reduced survival from 6.80 to 5.69 years. D, High CD8+ infiltration and high tumor
cytoplasmic androgen receptor expression reduced survival from 7.06 to 5.17 years. Censor lines indicate loss of patient follow‐up
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is the pro‐inflammatory cytokines secreted by local inflammatory
infiltrate, such as IL‐6, IL‐8, and TNF‐α that stimulates AR signaling
independent of androgens for example via JAK‐STAT, RAS‐RAF‐
MAPK, PI3K‐AKT, and nuclear factor B (NF‐κB) pathways.28
Following unsupervised hierarchal clustering of the frozen
TRUS prostate biopsies, two classes separated the cohort into
patients expressing significantly higher KLK3 expression in class 1
and lower KLK3 expression in class 2 (P = .016). We discovered 54
genes were DE in class 1 samples versus class 2 samples including
the overexpression of MAPK14, a key mediator of MAPK signaling
implicated in controlling cell death and survival.29,30 Upregulation
of MAPK signaling as a result of IL‐6 is involved in the develop-
ment of castrate resistant CaP.31 Furthermore, Wegiel et al also
identified IL‐6 activated PI3K signaling in CaP, in which we in-
terestingly found a key member of this signaling pathway, PI3KCA,
differentially and over expressed in class 1 high KLK3 expressing
biopsies. Additionally, overexpression of NFκB was observed in
high KLK3 expressing biopsies, a gene involved in regulating IL‐8
expression and promoting chemotaxis. Upregulation of this gene
and NF‐κB/RELA signaling is observed following androgen stimu-
lation of androgen‐dependent LNCaP cells.18 However, contra-
dictory to our findings of CASP‐1 overexpression, downregulation
of caspase‐1 is observed in breast cancer, and when knocked out
provided a highly proliferative environment for colon epithelial
cells and the development of colon tumors.32‐34 Interestingly,
when we analyzed only those patients who were diagnosed with
CaP, all DE genes in cancer class 1 were also DE in all samples in
class 1 including EGRF, AKT1, CASP‐1, and NFκB. Furthermore, we
found multiple genes including PI3CA, PSMA, ERB3, and IL1R all to
significantly correlate with increased AR expression, a poor prog-
nostic marker of CaP. Therefore, we decided to explore how
T‐Lymphocyte infiltration within the tumor microenvironment was
associated with CaP specific survival and if it associated with AR
expression.
Steiner et al reported a significant increase in infiltrating CD3+
cells in benign prostatic hyperplasia when compared with normal to
the normal prostate.35 However, contradictory to this, high CD3+
infiltrating T‐cells have a positive prognostic effect in many can-
cers.36 We observed high CD3+ T‐lymphocyte infiltration
significantly reduced cancer specific survival in hormone‐naïve CaP
(P = .018). Furthermore, this correlated with high TC AR expression
(c.c = 0.278 and P = .000232) and when patients expressed high
CD3+ infiltration and high AR expression, cancer specific survival
reduced significantly. However, Patnaik et al identified that following
blocking AR with a DNA vaccine in androgen sensitive mice, CD3+ T‐
cell infiltration increased and prolonged CaP recurrence.37 Ad-
ditionally, we explored how CD8+ cytotoxic T‐cells effects survival
and discovered high CD8+ infiltration reduced cancer specific sur-
vival and associated with high TC AR expression. High CD8+ and high
AR expression significantly reduced survival from 7.06 to 5.17 years.
However, conflicting results have been observed in triple negative
breast cancer, with high CD8+ T‐cell infiltration reducing breast
cancer mortality.38 In many cancers, high CD8+ infiltration is a fa-
vorable prognostic marker, with many immunotherapies aiming at
stimulating CD8+ anti‐tumoural behavior via anti‐CTLA4 or anti‐
PDL1 immunotherapies. As such, in some cancers the lack of an intra‐
tumoural immune niches of stem‐like CD8 T‐cells is associated with
more progressive disease.39 Interestingly, high CD8+ infiltration also
associated with high pARser213 expression in hormone‐naïve tumors.
Serine 213 is a known site for AKT binding and becomes activated via
the PI3K/AKT cascade which is regulated by PTEN, a tumor sup-
pressor commonly deleted or mutated in 30% of primary and 100%
of metastatic CaP.40,41 When patients express a loss of PTEN this
associates with elevated CD8+ infiltration in the prostate tumor
microenvironment and significantly reduces time to recurrence from
diagnosis.12 However, the mechanism though which loss of PTEN
stimulates CD8+ infiltration remains unclear.
Together, our results have provided evidence that levels of T‐
cells in CaP microenvironment are associated with poor prognosis.
Controversial results have been demonstrated here suggesting a
poor prognostic effect of T‐lymphocyte infiltration in hormone‐naïve
disease and a strong association between AR expression as well as
androgen‐independent AR activation. However, how this is reflected
in castrate resistant disease is critical to provide prevention and
further therapeutic options for this lethal form of CaP.
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